Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Agnelli G, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Brüggenjürgen B, Levy P, Laeis P, Fronk EM, Zierhut W, Malzer T, Manu MC, Reimitz PE, Bramlage P, Cohen AT; ETNA-VTE-Europe investigators. Agnelli G, et al. Among authors: bruggenjurgen b. Thromb Res. 2020 Dec;196:297-304. doi: 10.1016/j.thromres.2020.09.001. Epub 2020 Sep 12. Thromb Res. 2020. PMID: 32950897
Health State In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With The New Eq-5d-5l Questionnaire At Baseline And 12-Month Follow-Up: Prefer In Af Registry.
Brüggenjürgen B, Schliephacke T, Darius H, De CR, Le HJ, Reimitz PE, Schilling RJ, Schwertfeger M, Zamorano JL, Kirchhof P. Brüggenjürgen B, et al. Value Health. 2014 Nov;17(7):A493. doi: 10.1016/j.jval.2014.08.1464. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201472 Free article. No abstract available.
Treatment Satisfaction In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With Pact-Q2 At Baseline And 12-Month Follow-Up: Prefer In Af Registry.
Brüggenjürgen B, Schliephacke T, Darius H, De CR, Le HJ, Reimitz PE, Schilling RJ, Schwertfeger M, Zamorano JL, Kirchhof P. Brüggenjürgen B, et al. Value Health. 2014 Nov;17(7):A497. doi: 10.1016/j.jval.2014.08.1484. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201497 Free article. No abstract available.
Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Castro DJ, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Cohen AT, et al. Among authors: bruggenjurgen b. Thromb J. 2018 May 1;16:9. doi: 10.1186/s12959-018-0163-7. eCollection 2018. Thromb J. 2018. PMID: 29719492 Free PMC article.
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Jimenez D, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Cohen AT, et al. Among authors: bruggenjurgen b. Thromb J. 2018 May 31;16:18. doi: 10.1186/s12959-018-0173-5. eCollection 2018. Thromb J. 2018. PMID: 29855634 Free PMC article.
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.
Cohen AT, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Brüggenjürgen B, Levy P, Laeis P, Fronk EM, Zierhut W, Malzer T, Manu MC, Reimitz PE, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Cohen AT, et al. Among authors: bruggenjurgen b. Eur J Intern Med. 2020 Dec;82:48-55. doi: 10.1016/j.ejim.2020.08.014. Epub 2020 Aug 18. Eur J Intern Med. 2020. PMID: 32826158
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R, Brüggenjürgen B, Darius H, Köhler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P. De Caterina R, et al. Among authors: bruggenjurgen b. Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21. Arch Cardiovasc Dis. 2018. PMID: 28942115 Free article.
78 results